People · Operator
Named in public records as an officer, director or promoter · active 2019–2024 · Other, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Blue Duck Express, Inc. | — | Other | Series B | $13.6M | $4.5M | 2019 |
| Aspicio Therapeutics, Inc. | — | Pharma | Pre-Seed | $400K | $1.8M | 2024 |
Michael Keane at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Keane on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Eric Bell | 1 | 7 |
| Paul Bell | 1 | 6 |
| Robert Brantman | 1 | 2 |
| Rafael Garcia | 1 | 2 |
| Andre Champagne | 1 | 2 |
| Johnny Vassallo | 1 | 1 |
| Peter Gomez | 1 | 1 |
| Adrienne Beck | 1 | 1 |
| Jeffrey Mangold | 1 | 1 |
| Roger Overby | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.